Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2025, Aurinia Pharmaceuticals Inc. reported revenue of $283M, up 20.4% year over year. Operating margin was 37.1% and net margin 101.5%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from AUPH's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $283M | 37.1% | 101.5% |
| FY2024 | $235M | -2.0% | 2.4% |
| FY2023 | $176M | -52.2% | -44.5% |
| FY2022 | $134M | -83.2% | -80.7% |
| FY2021 | $46M | -396.3% | -396.8% |
How does AUPH compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.